Hematology Clinical Trial Expertise

Millions of people are affected by blood disorders each year.  Treatments continue to advance in the hematology field with 1,900 clinical trials currently recruiting patients. Whether the disease is genetic or acquired, whether it has invaded the blood cells, platelets, bone marrow, vascular endothelium, or plasma proteins, Veristat is equipped to help bring your hematology  therapies to market.

Hematology Experience

Veristat has guided clients through the conduct of more than 100 clinical trials and nearly 20 regulatory agency submissions for blood diseases. Our experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic blood disorders and autoimmune blood diseases, as well as blood cancers.
hematology_experience.png

Our Malignant & Non-Malignant Blood Disease Expertise

malignant_blood_disorder_table
non-malignant_blood_disorder_experience

FDA Approval - The True Proof of Success

Veristat supports the first targeted therapy for adult patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 mutation.

"I have personally had the priviledge to work with a dedicated Agios team on the IND application, phase I study, and NDA submission for ivosidenib. I am thrilled to see TIBSOVO® receive FDA approval and look forward to seeing this therapy help improve the lives of patients with R/R AML."

Barbara Balser, VMD, Veristat Executive VP & Chief Scientific Officer

Learn More with These Resources
Case Study
Keeping Up with an Over-Performing Site Case Study

Find out how Veristat was able to expertly rescue the site management and monitoring activities for a  sponsor seven months into patient enrollment at the ...

download
Fact Sheet
Hematology Fact Sheet

Veristat's hematology experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic ...

download
White Paper
Successful Preparation Strategies for  NDA/MAA Marketing ...

No two new drug applications (NDAs) or marketing authorization applications (MAAs) are the same. With each submission come special constraints, unique partnership ...

download
Request A Proposal